# Colchicine After Electrocardioversion for Atrial Fibrillation

Study · id `cardio:ct-nct05890664` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05890664](<https://clinicaltrials.gov/study/NCT05890664>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05890664

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 416 participants.

## Technical summary

Registry record NCT05890664. Randomized; triple masking; primary purpose treatment. Start 2024-04-14 (actual); primary completion 2027-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 416 participants (planned count; ClinicalTrials.gov record NCT05890664, source copy `cardio:ctgov-nct05890664-2025-05-28`, retrieved 2026-10-26)
- Started: 2024-04-14 (actual) (ClinicalTrials.gov record NCT05890664, source copy `cardio:ctgov-nct05890664-2025-05-28`, retrieved 2026-10-26)
- Primary completion: 2027-03 (anticipated) (ClinicalTrials.gov record NCT05890664, source copy `cardio:ctgov-nct05890664-2025-05-28`, retrieved 2026-10-26)
- Completion: 2027-03 (anticipated) (ClinicalTrials.gov record NCT05890664, source copy `cardio:ctgov-nct05890664-2025-05-28`, retrieved 2026-10-26)
- Countries: Switzerland (ClinicalTrials.gov record NCT05890664, source copy `cardio:ctgov-nct05890664-2025-05-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05890664-2025-05-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Colchicine After Electrocardioversion for Atrial Fibrillation
- Acronym: COLECTRO-AF
- Condition: Atrial Fibrillation
- Condition: Cardiac Arrhythmia
- Intervention (Drug): Colchicine
- Intervention (Drug): Placebo
- Lead sponsor: University Hospital, Basel, Switzerland
- Lead sponsor class: OTHER
- Collaborator: Swiss Heart Foundation
- Collaborator class: OTHER
- Collaborator: Fondation Machaon, Switzerland, Genf
- Collaborator class: UNKNOWN
- Collaborator: Foundation for Cardiovascular Research Basel
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry intervention name matches this record: Colchicine (`cardio:colchicine`)
- Registry lists this organization as the lead sponsor: University Hospital, Basel, Switzerland (`cardio:org-university-hospital-basel-switzerland`)
- Registry lists this organization as a collaborator: Swiss Heart Foundation (`cardio:org-swiss-heart-foundation`)

## Provenance

Content hash: 537c02d7c4a69dbf20e3b5e4649238786cc05b5d4078acd53bab7120b0482743
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
